{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:33Z","timestamp":1792047153301,"version":"4.4.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP1AI158125"],"award-info":[{"award-number":["DP1AI158125"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ebola virus (EBOV), a member of the <jats:italic>Filoviridae<\/jats:italic> family of viruses and a causative agent of Ebola Virus Disease (EVD), is a highly pathogenic virus that has caused over twenty outbreaks in Central and West Africa since its formal discovery in 1976. The only FDA-licensed vaccine against Ebola virus, rVSV-ZEBOV-GP (Ervebo<jats:sup>\u00ae<\/jats:sup>), is efficacious against infection following just one dose. However, since this vaccine contains a replicating virus, it requires ultra-low temperature storage which imparts considerable logistical challenges for distribution and access. Additional vaccine candidates could provide expanded protection to mitigate current and future outbreaks. Here, we designed and characterized two multimeric protein nanoparticle subunit vaccines displaying 8 or 20 copies of GP\u0394mucin, a truncated form of the EBOV surface protein GP. Single-dose immunization of mice with GP\u0394mucin nanoparticles revealed that neutralizing antibody levels were roughly equivalent to those observed in mice immunized with non-multimerized GP\u0394mucin trimers. These results suggest that some protein subunit antigens do not elicit enhanced antibody responses when displayed on multivalent scaffolds and can inform next-generation design of stable Ebola virus vaccine candidates.<\/jats:p>","DOI":"10.3389\/fimmu.2022.942897","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:02:03Z","timestamp":1661331723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Multimerization of Ebola GP\u0394mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies"],"prefix":"10.3389","volume":"13","author":[{"given":"Abigail E.","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillie A.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev-micro-090817-062414","article-title":"Ebola: Lessons on vaccine development","volume":"72","author":"Feldmann","year":"2018","journal-title":"Annu Rev Microbiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3934\/publichealth.2019.4.502","article-title":"Recurrent ebolavirus disease in the democratic republic of Congo: update and challenges","volume":"6","author":"Inungu","year":"2019","journal-title":"AIMS Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola Virus disease: current vaccine solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"P505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0196546","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with ebolavirus and marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"P493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/infdis\/jiv532","article-title":"Stability of a vesicular stomatitis virus-vectored Ebola vaccine","volume":"213","author":"Arnemo","year":"2016","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejpb.2018.06.001","article-title":"Stability and suitability for storage and distribution of Ad26.ZEBOV\/MVA-BN\u00ae-Filo heterologous prime-boost Ebola vaccine","volume":"129","author":"Capelle","year":"2018","journal-title":"Eur J Pharma Biopharmaceutics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200487","article-title":"Modern subunit vaccines: Development, components, and research opportunities","volume":"8","author":"Moyle","year":"2013","journal-title":"ChemMedChem"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11087","DOI":"10.1021\/acsnano.9b03660","article-title":"Multilamellar vaccine particle elicits potent immune activation with protein antigens and protects mice against Ebola virus infection","volume":"13","author":"Fan","year":"2019","journal-title":"ACS Nano"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-m adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22867-w","article-title":"Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines","volume":"12","author":"He","year":"2021","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","article-title":"Processing of the Ebola virus glycoprotein by the proprotein convertase furin","volume":"95","author":"Volchkov","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"12463","DOI":"10.1128\/jvi.76.24.12463-12472.2002","article-title":"Covalent modifications of the Ebola virus glycoprotein","volume":"76","author":"Jeffers","year":"2002","journal-title":"J Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.044","article-title":"Ebola Viral glycoprotein bound to its endosomal receptor niemann-pick C1","volume":"164","author":"Wang","year":"2016","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1073\/pnas.96.6.2662","article-title":"Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-\u00c5 resolution","volume":"96","author":"Malashkevich","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/nature10348","article-title":"Ebola Virus entry requires the cholesterol transporter niemann-pick C1","volume":"96","author":"Carette","year":"2011","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal niemann-pick C1 is essential for Ebola virus infection","volume":"477","author":"C\u00f4t\u00e9","year":"2011","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1128\/jvi.80.8.4174-4178.2006","article-title":"Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein","volume":"80","author":"Schornberg","year":"2006","journal-title":"J Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110656","article-title":"Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection","volume":"308","author":"Chandran","year":"2005","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"P5860","DOI":"10.1074\/jbc.M116.768168","article-title":"Mechanistic understanding of n-glycosylation in Ebola virus glycoprotein maturation and function","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Sci (1979)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12041","article-title":"Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles","volume":"7","author":"He","year":"2016","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1021\/acscentsci.0c01405","article-title":"A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice","volume":"7","author":"Powell","year":"2021","journal-title":"ACS Cent Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"P1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Sci (1979)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Sci (1979)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/v12050513","article-title":"Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays","volume":"12","author":"Crawford","year":"2020","journal-title":"Viruses"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0086","DOI":"10.1128\/mBio.00862-13","article-title":"Comprehensive functional analysis of n-linked glycans on ebola virus GP1","volume":"5","author":"Lennemann","year":"2014","journal-title":"mBio"},{"key":"B37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid a and QS21 induce strong and persistent humoral and T cell responses against hepatitis b surface antigen in healthy adult volunteers","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.10.078","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid a and QS-21 induce strong humoral and cellular immune responses against hepatitis b surface antigen which persist for at least 4 years after vaccination","volume":"33","author":"Leroux-Roels","year":"2015","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants","volume":"291","author":"Marty-Roix","year":"2016","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2018.01.003","article-title":"High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test","volume":"254","author":"Konduru","year":"2018","journal-title":"J Virol Methods"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Sci (1979)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162446","article-title":"Ebolavirus glycoprotein fc fusion protein protects Guinea pigs against lethal challenge","volume":"11","author":"Konduru","year":"2016","journal-title":"PLoS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.942897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:02:07Z","timestamp":1661331727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.942897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2022.942897"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.942897","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"article-number":"942897"}}